カテゴリ： Allied Market Research, 世界, 医療/バイオ

放射性医薬品のグローバル市場（2023-2032）：テクネチウム99m、フッ素18、ヨウ素I、ガリウム68、その他

■ 英語タイトル：Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP124）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP124
■ 発行日：2023年4月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：300
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[放射性医薬品のグローバル市場（2023-2032）：テクネチウム99m、フッ素18、ヨウ素I、ガリウム68、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

放射性医薬品市場の2022年の市場規模は52億ドルで、2023年から2032年までの年平均成長率は10.2%で、2032年には137億ドルに達すると予測されています。放射性医薬品は、さまざまな疾患のモニタリング、診断、治療に使用される放射性医薬品と定義されます。放射性医薬品は治療や診断の目的で広く使用されています。治療目的では、放射性医薬品を一定量投与することで、特定の疾患部位に適切な治療用量の放射線を照射します。一方、診断では、臓器の機能を観察するために少量の放射線を身体に照射します。放射性医薬品は半減期が短いため、製造後すぐに患者に投与する必要があります。
放射性医薬品市場は、がん、神経疾患、心血管疾患などの対象疾患の有病率の上昇や、医療用画像診断における放射性医薬品の使用の増加によって牽引されています。世界がん研究基金インターナショナルによると、2020年には世界で約1,810万人が新たにがんと診断されると報告されています。放射性医薬品は、がんの診断や治療に放射性物質を使用します。がんの診断に使用される放射性医薬品は、Axumin、PYLARIFY、CERIANNA、Locametz、Lymphoseekなどがあります。さらに研究者たちは、放射線療法をがん細胞に特異的かつ直接送達するように設計された新規放射性医薬品の開発も目指しています。放射線治療の需要の急増や、癌やその他の対象疾患の診断件数の増加が、市場の成長を後押ししています。

さらに、放射性医薬品は陽電子放射断層撮影（PET）イメージング中に使用され、生体組織の検査を支援します。前立腺、心臓、アミロイドイメージングの増加により、PET検査のニーズが急増。医療用画像診断の需要増加により、放射性医薬品のニーズが急増し、放射性医薬品市場の成長を後押ししています。

例えば、2023年3月、バイオテクノロジー企業であるTelix Pharmaceuticals社は、Illuccixの米国食品医薬品局（FDA）承認を発表しました。Ga68を放射性標識した放射性診断薬です。適応は、前立腺癌男性における前立腺特異的膜抗原（PSMA）陽性病変のポジトロン断層撮影（PET）です。また、2022年3月、米国食品医薬品局（FDA）は、成人前立腺がん患者の治療薬としてPluvictoを承認したと発表しました。Pluvictoは、ルテチウムLu 177ビピボタイドテトラキセタンという放射性同位元素を含む、初のPSMA標的放射性医薬品です。

加えて、医療業界における研究開発活動の活発化も市場の成長を後押ししています。コインブラ大学健康応用核科学研究所は、診断用放射性医薬品の現在および将来の需要に対応するため、研究開発活動に積極的に取り組んでいます。さらに、放射性医薬品に関する臨床試験の増加が放射性医薬品市場の成長を後押ししています。さらに、医療における研究開発活動への投資の増加が市場の成長をさらに後押ししています。しかし、市場成長を阻害する要因としては、吐き気、嘔吐、腹痛、背部痛など、放射性医薬品の使用に伴う副作用が挙げられます。
一方、放射性医薬品産業の存在、放射性医薬品の研究開発活動の増加、新興市場における成長の可能性は、予測期間中に放射性医薬品に大きな機会をもたらすと期待されています。

放射性医薬品市場は、放射性同位元素、用途、タイプ、エンドユーザー、地域によって区分されます。放射性同位元素ベースでは、市場はテクネチウム-99m、フッ素-18、ヨウ素I、ガリウム-68、その他に分類されます。その他は、インジウム-111、イットリウム-90、ルテチウムLu-177、銅-64、炭素-14、炭素-11、ストロンチウム-89、ルビジウム-82、ラジウム-223、窒素-13、モリブデン、ガリウム-67、タリウム-201、キセノン-133などがあります。用途別では、がん、心臓病、その他で分類されます。タイプ別では、診断用、治療用で分けられます。エンドユーザー別では、病院・診療所、医療画像診断センター、その他に分類されます。その他には、診断センター、研究機関などが含まれます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、英国、フランス、スペイン、イタリア、その他の欧州）、アジア太平洋（インド、中国、オーストラリア、日本、韓国、その他のアジア太平洋）、LAMEA（ブラジル、サウジアラビア、南アフリカ、その他のLAMEA）で調査されています、 Curium Pharma、Eli Lilly and Company、General Electric Company、Iso-Tex Diagnostics, Inc、Jubilant Pharmova Limited、Lantheus Holdings, Inc、Novartis AG、Siemens AG、Bayerなどの企業情報が含まれています。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2032年までの放射性医薬品市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、放射性医薬品市場の有力な機会を特定します。
主な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
放射性医薬品市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解するのに役立ちます。
地域別および世界の放射性医薬品市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主な市場セグメント
エンドユーザー別
病院・診療所
医療画像診断センター
その他

放射性同位元素別
ヨウ素I
ガリウム68
その他
テクネチウム99m
フッ素18

用途別
癌
循環器
その他

タイプ別
診断薬
治療用

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ Bayer AG
○ Cardinal Health Inc.
○ Curium Pharma
○ Eli Lilly and Company
○ General Electric Company
○ Iso-Tex Diagnostics, Inc
○ Jubilant Pharmova Limited
○ Lantheus Holdings, Inc.
○ Novartis AG
○ Siemens AG

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：放射性医薬品市場、放射性同位元素別
第5章：放射性医薬品市場、用途別
第6章：放射性医薬品市場、タイプ別
第7章：放射性医薬品市場、エンドユーザー別
第8章：放射性医薬品市場、地域別
第9章：競争状況
第10章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of cancer, cardiovascular and neurological disease
3.4.1.2. Increase in demand for medical imaging
3.4.1.3. Increase in number of product approval for radiopharmaceuticals

3.4.2. Restraints
3.4.2.1. Side effect associated with radiopharmaceuticals

3.4.3. Opportunities
3.4.3.1. Presence of radiopharmaceutical industry
3.4.3.2. Increase in R&D activities for radiopharmaceuticals

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Technetium 99m
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Fluorine 18
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Iodine I
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Gallium 68
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cancer
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cardiology
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market size and forecast
6.2. Diagnostic
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Therapeutic
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospitals and clinics
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Medical Imaging centers
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: RADIOPHARMACEUTICALS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Radioisotope
8.2.3. Market size and forecast, by Application
8.2.4. Market size and forecast, by Type
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Radioisotope
8.2.6.1.3. Market size and forecast, by Application
8.2.6.1.4. Market size and forecast, by Type
8.2.6.1.5. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Radioisotope
8.2.6.2.3. Market size and forecast, by Application
8.2.6.2.4. Market size and forecast, by Type
8.2.6.2.5. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Radioisotope
8.2.6.3.3. Market size and forecast, by Application
8.2.6.3.4. Market size and forecast, by Type
8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Radioisotope
8.3.3. Market size and forecast, by Application
8.3.4. Market size and forecast, by Type
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Radioisotope
8.3.6.1.3. Market size and forecast, by Application
8.3.6.1.4. Market size and forecast, by Type
8.3.6.1.5. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Radioisotope
8.3.6.2.3. Market size and forecast, by Application
8.3.6.2.4. Market size and forecast, by Type
8.3.6.2.5. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Radioisotope
8.3.6.3.3. Market size and forecast, by Application
8.3.6.3.4. Market size and forecast, by Type
8.3.6.3.5. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Radioisotope
8.3.6.4.3. Market size and forecast, by Application
8.3.6.4.4. Market size and forecast, by Type
8.3.6.4.5. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Radioisotope
8.3.6.5.3. Market size and forecast, by Application
8.3.6.5.4. Market size and forecast, by Type
8.3.6.5.5. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Radioisotope
8.3.6.6.3. Market size and forecast, by Application
8.3.6.6.4. Market size and forecast, by Type
8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Radioisotope
8.4.3. Market size and forecast, by Application
8.4.4. Market size and forecast, by Type
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Radioisotope
8.4.6.1.3. Market size and forecast, by Application
8.4.6.1.4. Market size and forecast, by Type
8.4.6.1.5. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Radioisotope
8.4.6.2.3. Market size and forecast, by Application
8.4.6.2.4. Market size and forecast, by Type
8.4.6.2.5. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Radioisotope
8.4.6.3.3. Market size and forecast, by Application
8.4.6.3.4. Market size and forecast, by Type
8.4.6.3.5. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Radioisotope
8.4.6.4.3. Market size and forecast, by Application
8.4.6.4.4. Market size and forecast, by Type
8.4.6.4.5. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Radioisotope
8.4.6.5.3. Market size and forecast, by Application
8.4.6.5.4. Market size and forecast, by Type
8.4.6.5.5. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Radioisotope
8.4.6.6.3. Market size and forecast, by Application
8.4.6.6.4. Market size and forecast, by Type
8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Radioisotope
8.5.3. Market size and forecast, by Application
8.5.4. Market size and forecast, by Type
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Radioisotope
8.5.6.1.3. Market size and forecast, by Application
8.5.6.1.4. Market size and forecast, by Type
8.5.6.1.5. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Radioisotope
8.5.6.2.3. Market size and forecast, by Application
8.5.6.2.4. Market size and forecast, by Type
8.5.6.2.5. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Radioisotope
8.5.6.3.3. Market size and forecast, by Application
8.5.6.3.4. Market size and forecast, by Type
8.5.6.3.5. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Radioisotope
8.5.6.4.3. Market size and forecast, by Application
8.5.6.4.4. Market size and forecast, by Type
8.5.6.4.5. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Curium Pharma
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Key strategic moves and developments
10.2. Cardinal Health Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. General Electric Company
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.7. Key strategic moves and developments
10.4. Iso-Tex Diagnostics, Inc
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.5. Lantheus Holdings, Inc.
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Siemens AG
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Jubilant Pharmova Limited
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Novartis AG
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Bayer AG
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Eli Lilly and Company
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. RADIOPHARMACEUTICALS MARKET FOR TECHNETIUM 99M, BY REGION, 2022-2032 ($MILLION)
TABLE 03. RADIOPHARMACEUTICALS MARKET FOR FLUORINE 18, BY REGION, 2022-2032 ($MILLION)
TABLE 04. RADIOPHARMACEUTICALS MARKET FOR IODINE I, BY REGION, 2022-2032 ($MILLION)
TABLE 05. RADIOPHARMACEUTICALS MARKET FOR GALLIUM 68, BY REGION, 2022-2032 ($MILLION)
TABLE 06. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 08. RADIOPHARMACEUTICALS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 09. RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY REGION, 2022-2032 ($MILLION)
TABLE 10. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 12. RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 13. RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 15. RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 16. RADIOPHARMACEUTICALS MARKET FOR MEDICAL IMAGING CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. RADIOPHARMACEUTICALS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 24. U.S. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 25. U.S. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. U.S. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. U.S. RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. CANADA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 29. CANADA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. CANADA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 31. CANADA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. MEXICO RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 33. MEXICO RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. MEXICO RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 35. MEXICO RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 37. EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 40. EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 41. GERMANY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 42. GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 43. GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 44. GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 46. FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 48. FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. UK RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 50. UK RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. UK RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. UK RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 53. ITALY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 54. ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 57. SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 58. SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 60. SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 70. JAPAN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 71. JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 73. JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 74. CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 75. CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 77. CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 78. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 79. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 81. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 82. INDIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 83. INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 85. INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 94. LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 95. LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 97. LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 98. LAMEA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 99. BRAZIL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 100. BRAZIL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 101. BRAZIL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 102. BRAZIL RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 103. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 104. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 105. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 107. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 108. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 109. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 110. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 111. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 113. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 115. CURIUM PHARMA: KEY EXECUTIVES
TABLE 116. CURIUM PHARMA: COMPANY SNAPSHOT
TABLE 117. CURIUM PHARMA: PRODUCT SEGMENTS
TABLE 118. CURIUM PHARMA: PRODUCT PORTFOLIO
TABLE 119. CURIUM PHARMA: KEY STRATERGIES
TABLE 120. CARDINAL HEALTH INC.: KEY EXECUTIVES
TABLE 121. CARDINAL HEALTH INC.: COMPANY SNAPSHOT
TABLE 122. CARDINAL HEALTH INC.: PRODUCT SEGMENTS
TABLE 123. CARDINAL HEALTH INC.: PRODUCT PORTFOLIO
TABLE 124. CARDINAL HEALTH INC.: KEY STRATERGIES
TABLE 125. GENERAL ELECTRIC COMPANY: KEY EXECUTIVES
TABLE 126. GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT
TABLE 127. GENERAL ELECTRIC COMPANY: PRODUCT SEGMENTS
TABLE 128. GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO
TABLE 129. GENERAL ELECTRIC COMPANY: KEY STRATERGIES
TABLE 130. ISO-TEX DIAGNOSTICS, INC: KEY EXECUTIVES
TABLE 131. ISO-TEX DIAGNOSTICS, INC: COMPANY SNAPSHOT
TABLE 132. ISO-TEX DIAGNOSTICS, INC: PRODUCT SEGMENTS
TABLE 133. ISO-TEX DIAGNOSTICS, INC: PRODUCT PORTFOLIO
TABLE 134. LANTHEUS HOLDINGS, INC.: KEY EXECUTIVES
TABLE 135. LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 136. LANTHEUS HOLDINGS, INC.: PRODUCT SEGMENTS
TABLE 137. LANTHEUS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 138. LANTHEUS HOLDINGS, INC.: KEY STRATERGIES
TABLE 139. SIEMENS AG: KEY EXECUTIVES
TABLE 140. SIEMENS AG: COMPANY SNAPSHOT
TABLE 141. SIEMENS AG: PRODUCT SEGMENTS
TABLE 142. SIEMENS AG: PRODUCT PORTFOLIO
TABLE 143. JUBILANT PHARMOVA LIMITED: KEY EXECUTIVES
TABLE 144. JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT
TABLE 145. JUBILANT PHARMOVA LIMITED: PRODUCT SEGMENTS
TABLE 146. JUBILANT PHARMOVA LIMITED: SERVICE SEGMENTS
TABLE 147. JUBILANT PHARMOVA LIMITED: PRODUCT PORTFOLIO
TABLE 148. JUBILANT PHARMOVA LIMITED: KEY STRATERGIES
TABLE 149. NOVARTIS AG: KEY EXECUTIVES
TABLE 150. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 151. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 152. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 153. NOVARTIS AG: KEY STRATERGIES
TABLE 154. BAYER AG: KEY EXECUTIVES
TABLE 155. BAYER AG: COMPANY SNAPSHOT
TABLE 156. BAYER AG: PRODUCT SEGMENTS
TABLE 157. BAYER AG: PRODUCT PORTFOLIO
TABLE 158. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 159. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 160. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 161. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 162. ELI LILLY AND COMPANY: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 放射線治療のグローバル市場（2023年-2030年）：ヨウ素131、ヨウ素123、ガリウム68、ルテチウム177、18F＆Y-90、その他
  • 核医学・放射性医薬品のグローバル市場（2018～2029）：種類別、産業別、地域別
  • 慢性腎臓病（CKD）治療のグローバル市場（2023-2032）：薬剤、透析
  • 動物用歯科機器のグローバル市場（2023-2032）：手用器具、機器、消耗品
  • 腸疾患検査のグローバル市場（2023-2032）：試薬＆消耗品、機器
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP124 )"放射性医薬品のグローバル市場（2023-2032）：テクネチウム99m、フッ素18、ヨウ素I、ガリウム68、その他" (英文：Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。